Drug Profile
Anti-PDL1 chimeric switch receptor modified T-cell therapy - Marino Biotechnology
Alternative Names: Anti-PD-L1-chimeric-switch-receptor-modified-T-cell-therapy; Autologous-anti-PD-L1-chimeric-switch-receptor-modified-T-cell-therapy; Chimeric-switch-receptor-engineered-T-cells-redirected-to-PD-L1-therapy; CSR-T-PD-L1-cell-therapyLatest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Marino Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma; Solid tumours
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Recurrent) in China (IV, Infusion)
- 28 Aug 2019 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent, Second-line therapy or greater) in China (IV, Infusion)
- 01 Aug 2016 Phase-I clinical trials in Solid tumours (Metastatic disease, Recurrent) in China (IV) (NCT02930967)